 |
|
|
Prostaglandin F2alpha
|
|
| Systematic (IUPAC) name | |
| (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)- 3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid | |
| Identifiers | |
| CAS number | 38562-01-5 (tromethamine) |
| ATC code | G02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H34O5 |
| Mol. mass | 354.48 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 3 to 6 hours in amniotic fluid, less than 1 minute in blood plasma |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous (to induce labor), intra-amniotic (to induce abortion) |
Prostaglandin F2α (PGF2α in prostanoid nomenclature) is pharmaceutically termed Dinoprost (INN, is a naturally-occurring prostaglandin used in medicine to induce labor and as an abortifacient.
In domestic mammals, it is produced by the uterus when stimulated by oxytocin, in the event that there has been no implantation during the follicular phase. It acts on the corpus luteum to cause luteolysis, forming a corpus albicans and stopping the production of progesterone. Action of PGF2α is dependent on the number of receptors on the corpus luteum membrane.
Mechanism of action
PGF2α acts by binding to the prostaglandin F2α receptor.
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
